Kilickap, S.Demirci, U.Bugdayci, F.Tural, D.Korkmaz, T.Paydas, S.Yilmaz, C.Turna, H.Sezer, A.Cinkir, H. YesilOkutur, K.Erman, M.Eralp, Y.Cabuk, D.Isikdogan, A.Demirkazik, A.Karaoglu, A.Yazilitas, D.Senler, F. CayYumuk, P. F.Coskun, H.Yildiz, I.Oztop, I.Beypinar, I.Aydin, K.Kaplan, M.Meydan, N.Olmez, O. F.Ozyilkan, O.Seber, S.Arslan, C.Sendur, M. A.Cicin, I.2023-02-212023-02-212019-01-0110.1016/j.jtho.2019.08.1166https://hdl.handle.net/11443/2813http://dx.doi.org/10.1016/j.jtho.2019.08.1166Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in TurkeyArticleWOS:000492162203082